Detalhe da pesquisa
1.
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2.
Proc Natl Acad Sci U S A;
121(6): e2317756121, 2024 Feb 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38300868
2.
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Cancer Discov;
13(9): 2012-2031, 2023 09 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37270847
3.
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.
Mol Cancer Ther;
14(7): 1625-36, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25911688